Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 2016 | 4 | 2 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 2016 | 6 | 1 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 2016 | 7 | 1 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 2016 | 8 | 1 |
| Teijin Pharma Limited, Medical Devices Deals, 2010 to YTD 2016 | 9 | 1 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016 | 10 | 1 |
| Teijin Pharma Limited, Pharmaceuticals &Healthcare, Deal Details | 11 | 13 |
| Partnerships | 11 | 1 |
| Teijin Pharma Enters into Discovery Agreement with PeptiDream | 11 | 1 |
| Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies | 12 | 1 |
| Teijin Pharma Extends Co-Marketing Agreement With Menarini For TMX-67 | 13 | 1 |
| NovAliX Enters Into Multi-Target Integrated Drug Discovery Collaboration With Teijin Pharma | 14 | 1 |
| Teijin Pharma Enters Into Distribution Agreement With Astellas Pharma For Febuxostat | 15 | 1 |
| Teijin Pharma Enters Into Co-Marketing Agreement With Takeda Pharma North America For TMX-67 | 16 | 1 |
| Teijin Pharma Enters Into Co-Marketing Agreement With Algorithm For TMX-67 | 17 | 1 |
| Teijin Pharma Enters Into Co-Marketing Agreement With Menarini Group For TMX-67 | 18 | 1 |
| Licensing Agreements | 19 | 1 |
| Teijin Pharma Enters into Licensing Agreement with Versartis | 19 | 2 |
| Teijin Pharma Enters Into Licensing Agreement With Pulmagen Therapeutics For ADC3680 | 21 | 1 |
| Teijin Pharma Enters Into An Agreement With Astellas Pharma | 22 | 2 |
| Teijin Pharma Limited - Key Competitors | 24 | 1 |
| Key Employees | 25 | 1 |
| Locations And Subsidiaries | 26 | 1 |
| Head Office | 26 | 1 |
| Other Locations &Subsidiaries | 26 | 1 |
| Appendix | 27 | 1 |
| Methodology | 27 | 1 |
| About GlobalData | 27 | 1 |
| Contact Us | 27 | 1 |
| Disclaimer | 27 | 1 |